Sentence examples for patentability of from inspiring English sources

More specifically, we analyzed the users' demographics, geographic locations, and attitudes toward the CHEO position on gene patents and the patentability of human genes in principle.

Indeed, Rosenfeld and Mason [ 1] rely on their results to propose that 'the Supreme Court and Congress should limit the patenting of existing nucleotide sequences because of their broad scope and non-specificity in the human genome.' We note that none of the above necessarily reflects on the position of the authors [ 1] in the ongoing debate regarding the patentability of 'gene patents'.

The USPTO is still considering whether to reexamine the patentability of Versata's '350 patent in a separate ex-parte reexamination proceeding based on prior art, notes  Arner.

The requirement of non-obviousness or of the existence of an inventive step found in all national patent systems thus theoretically prevents the patentability of plant varieties, unless the criteria for such patentability are revised or re-interpreted with lower standards (Barton and Berger [2001]).

He said that although gene patents had been issued for decades, the patentability of genes had never been examined in court.

Our analysis of tweets reveals an expectation that the CHEO lawsuit will provide an opportunity to clear the confusion on gene patents by establishing a legal precedent on the patentability of human genes in Canada.

"The term 'selection invention' means we are able to select a specific compound that meets the terms of patentability out of a very large chemical class," explained Gary Lyons, the president and chief executive of Neurocrine Biosciences Inc. in San Diego, which won the recent patent for a new insomnia treatment.

Awrey states that the main incentive of financial intermediaries to innovate is to recreate the monopolistic condition that is usually lost due to the non-patentability of financial innovations.

Recent advances in computational methods for polymorph prediction and some of the important regulatory and patentability aspects of polymorphs are also discussed in the chapter.

Some of these policies include: (1) reinforcing the research exemption for academic researchers, (2) raising the "bar" for the criteria of patentability, (3) restricting the scope of patents, (4) disclosing conflicts of interest related to DNA patents, (5) sharing the economic benefits of patenting with patients, and (6) providing insurance coverage for some types of genetic tests.

Emergence of a new polymorph can have deep implications on the solid form selection, regulation, and patentability aspects of a drug.